Imperative Care, a medical technology company focused on thromboembolic disease treatments, has appointed Jay Martin as Chief Commercial Officer. Martin will lead commercial strategy, expand strategic partnerships and build infrastructure to support the company's growth and commercialisation efforts. Martin brings over 25 years of executive leadership experience in medical devices, robotics and imaging. Most recently, he served as President of VulcanForms, where he helped build a backlog exceeding $1 billion in 18 months. He previously spent eight years at Globus Medical, serving as President of Imaging, Navigation and Robotics, and was part of the leadership team that grew the company from approximately $400 million to over $2 billion in revenue. The Campbell, California-based company develops treatments for patients suffering from blood clot formation in veins and arteries.

Imperative Care, Inc., a medical technology company focused on advancing treatments for patients suffering from thromboembolic disease, today announced the

Imperative Care, a medical technology company treating thromboembolic disease, has closed an oversubscribed $100 million convertible note financing. The round was co-led by new investors Elevage Medical Technologies and Perceptive Advisors, alongside existing investor Catalio Capital Management. New investors Longaeva Partners and Brown Advisory participated, with support from existing backers including Ally Bridge Group and Bain Capital Life Sciences. Evan Melrose, CEO of Elevage Medical Technologies, has joined Imperative Care's board of directors. The funding will support commercialisation of the company's stroke and vascular thrombectomy portfolios, next-generation product development including the Telos robotic platform, and clinical evidence generation. Imperative Care's products have been used in over 78,000 procedures commercially. BofA Securities and J.P. Morgan served as joint placement agents.